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Abstract: 
The aim of the present research was to design and characterize delayed release Multi Unit Particles 
(MUPS). These were produced primarily for the purpose of oral modified release dosage forms having 
gastro resistant and delayed-release properties. During the development of MUPS agglomeration, 
generations of fines and twins formation are identified as critical issues.  The delayed release multiple 
units were prepared by layering drug suspension using Wurster technology. The prepared multi unit 
particulates consist of successive layers of drug layer (Esomeprazole), barrier coat and enteric coat 
(Eudragit L30 D55) on to inert seeds (sugar spheres #50/60). Finally the MUPS are filled into capsules 
(white to off white hard gelatin). The MUPS were evaluated for drug content, moisture content, particle 
size distribution, good flow properties and the filled capsules were evaluated for acid resistance (0.1N 
HCl for 2 hrs) test and In-vitro drug release (pH 6.8 phosphate buffer)  and compared with the innovator 
product. The characterization of pellets was completed and capsules were packed into HDPE bottle (60cc 
with 33mm closure) and subjected to accelerated stability testing (40°C/75%RH) for six months and 
results were compared with initial results. 
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INTRODUCTION: 
Recent approach that comes into existence is the one 
that combine the feature of both controlled release 
tablets and modified release capsules in one dosage 
form. Such system is known as MUPS technology. 
The delayed release systems can be used to protect 
the drug from degradation in the low pH environment 
of stomach and avoid the irritation by drug. The 
Esomeprazole is selected as a model drug, the drug 
was coated onto sugar spheres #50/60. Then further 
coating was followed by barrier coating was using 
hydrophobic agents and Enteric coating was done by 
using Eudragit polymer and plasticizer. In barrier 
coating HPC acts as binder[1-3]. The development of 
formulation was done by optimizing percentage (%) 
build up of Barrier and Enteric coating. Finally, 
barrier coating percentage was optimized at 55%, and 
enteric coating at 50%. The formulation was 
analyzed in 0.1N HCl up to 2hrs, the acid degradation 
was not exceeded 10%, and then followed by pH 6.8 
phosphate buffer medium. Optimized the percentage 
drug release profile of Esomeprazole to be 
comparable with the Innovator product and 
evaluation of the formulation developed was found to 
be satisfactory [4-7]. 
MATERIALS AND METHODS 
Materials: 
Esomeprazole Magnesium Trihydrate was procured 
from Hetero drugs, Povidone (Kollidon  30, BASF, 
Germany), Polysorbate 80 (Kolliphore PS 80, 
BASF), Hydroxy propyl cellulose (klucel LF), Sugar 
Spheres (#50/60) (Colorcon), Hydroxy Propyl methyl 
Cellulose E5 (Dow Chemical’s), Talc (Luzenac 
Pharma), Eudragit L30 D55 (Evonic polymers), 
Glyceryl Mono Stearate (BASF), Poloxamer 188 
(BASF), Magnesium Oxide (Granules India), 
Triethyl citrate (Vertellus), Simethicone (Dow 
corning), methanol (Rankem chemicals), glacial 
acetic acid (Rankem chemicals), Acetyl Tributyl 
Citrate (Vertellus), Di Sodium Hydrogen Phosphate 
(Rankem chemicals) were used in trials. 
Methods    
Acid resistance  
Acid resistance of Esomeprazole multi unit 
particulates contained capsule placed in 300 mL of 
0.1N HCl medium up to 2hrs. When the test was 
completed, immediately discarded the medium from 
the vessel and collected the pellets.  
Dissolution  
The dissolution test carried out by USP method, the 
capsule containing pellets was placed in a 0.1N HCl 
medium followed by pH 6.8 phosphate buffer. 
Assay  
10 mg of omeprazole in 250 ml volumetric flask 
added 25 ml methanol sonicate for 15 mins, then 
added 50 ml of diluents and finally make up with 
water sonicate it up to 5 mins. Taken 5 ml of solution 
from above stock solution and transferred it 25 ml 
volumetric flask, then 2 ml of 0.25N NaOH was 
added and volume was made-up with diluent. Finally, 
5-10 ml sample was taken and filtered through 
0.45micron filter paper. The sample was Stored in a 
dark place. 
Preformulation Studies 
The pre-formulation studies of  API and excipients 
like physical parameters evaluation like moisture 
content, solubility, bulk density, Drug- Excipient 
compatibility studies of API and excipients. 
 
Characterization of API 
Table 01: characterization of API 
S. No. Test Result 
1 Description Cream color hygroscopic powder 
2 Solubility Complies 
3 Moisture content 5.30% 
4 Bulk density g/cc 0.34 
5 Compressibility index % 22.7 
6 Hausner's ratio 0.73 
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Table 02: Drug-Excipient compatibility studies 
SNO 
INGREDIENT 
NAME 
RATIO 
INITIAL 
OBSERVATION 
1st  
WEEK 
2nd  
WEEK 
3rd 
WEEK 
4th 
WEEK 
1 
API : Hydroxy 
propyl methyl 
cellulose 
1:0.25 White to off white NC NC NC NC 
2 
API : Hydroxy 
propyl cellulose 
1:0.25 White to off white NC NC NC NC 
3 API : Talc 1:1 White to off white NC NC NC NC 
4 
API : Magnesium 
stearate 
1:0.1 White to off white NC NC NC NC 
5 
API : Glyceryl mono 
stearate II 
1:0.2 White to off white NC NC NC NC 
6 API : Tween 80 1:0.01 White to off white NC NC NC NC 
7 
API : Eudragit L30 
D55 
1:0.5 White to off white NC NC NC NC 
8 
API : Try ethyl 
citrate 
1:0.2 White to off white NC NC NC NC 
9 API : Sugar spheres 1:1 White to off white NC NC NC NC 
10 
API : Magnesium 
oxide HA 
1:0.01 White to off white NC NC NC NC 
 
11 
API: Poloxamer 1:0.1 White to off white NC NC NC NC 
12 API : Povidone k 30 1:0.5 White to off white NC NC NC NC 
 
Drug and Excipient compatibility studies 
The drug and excipient compatibility studies were 
performed by physical method. In physical studies 
the drug and individual excipient, drug and all 
excipients and placebo was stored in 40oC/75% RH 
in glass vials up to 4 weeks. The samples were 
observed for any colour changes in particular 
duration of storage. 
Drug-Excipient compatibility studies (physical 
evaluation at 40°C/75%RH). 
The following steps involved in formulation of 
multi unit particulates 
1. Drug layering 
2. Barrier coating  
3. Enteric coating 
1. Drug layering: The Drug dispersion was prepared 
based on the thickness (or) viscosity and coated onto 
the pellets with the assuming percentage efficiency. 
The problems like appearance of foam in the coating 
solution observed which created fines. It was 
rectified by the adding anti foaming agent for 
avoiding the foam during preparation of drug coating 
solution. 
2. Barrier coating: The Barrier coating dispersion 
was prepared by adding different hydrophobic agents 
like talc, magnesium stearate. The percentage build 
up of coating was optimized to ensure acid resistance 
and desired drug release profile.  
3. Enteric coating: The Enteric coating solution was 
prepared by adding anti tacking agent, plasticizer to 
the 30% Eudragit dispersion. The coating was done 
by maintaining low temperature. The main advantage 
of enteric coating is acid protection to the drug in 
acid media or low pH buffer media. 
Process parameters: The below table explains 
process parameters and their importance in the 
process optimization and their effects on the 
formulation.   
1. Product Temperature 
Product temperature affects the drug-layering pattern, 
drug loss during layering, spray drying of coating 
suspension and/or twins formation. All these effects 
influence assay and content uniformity. The product 
temperature does not influence the acid resistance or 
dissolution. 
2. Fluidization 
Fluidization of sugar beads affects the pattern of flow 
in the coating zone and also influences the uniformity 
of drug layering and efficiency of the process.  
Therefore, both assay and content uniformity are 
affected. Drug layering doesn’t have any impact on 
the acid resistance or dissolution. Hence the risk is 
considered to be low. 
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3. Atomization/Spray rate 
Atomization pressure decides the size of globules 
from spray gun and spray rate will influence the 
volume of suspension per unit time.  Globule size 
should be optimum since smaller size leads to spray 
drying and bigger globule size causes over wetting of 
beads and lumps formation. Spray rate should be 
optimum to achieve better assay and content 
uniformity.  Too low spray rate may lead to spray 
drying while high spray rate may cause over wetting 
and lumps formation.   
4. Drying/ curing   
The drying rate of temperature was high and they 
easily generated fines and improper coat on to the 
pellets. Drying rate affects the content uniformity, 
dissolution and acid resistance. The curing rate 
defined as simply the formation of film with high 
integrity, smoothness and avoiding the pinholes on to 
the each pellet with the help of minimum film 
formation temperature (MFT). The literature’s and 
polymer manufacturer recommended the curing time 
90 minutes at 40-45 °C temperature. 
Formulation  
The below formulation table explains about drug and 
their excipients, percentage coating and different 
concentrations used in each formulation. The 
formulation was divided into three parts like drug 
layer, barrier coat and enteric coat and each coating 
was done based on weight gain and percentage was 
calculated by initial weight of loaded batch and final 
weight of batch.   
Table 03: Formulation  
Ingredient F01 F02 F03 F04 F05 F06 F07 F08 F09 F10 
Drug layering (quantity in mg/unit) 
Sugar spheres 15 15 15 15 15 15 15 15 15 15 
Esomeprazole magnesium 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 
Hydroxy propyl methyl cellulose NA 6 6 6 6 6 6 6 6 6 
Povidone 8 NA NA NA NA NA NA NA NA NA 
Magnesium oxide 8 NA 6 6 6 6 6 NA NA NA 
Poloxamer 3 NA NA NA NA NA 1 2 2 3 
Tween 80 NA 0.6 0.6 NA NA NA 0.6 0.6 0.6 0.6 
Simethicone NA 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
Barrier coating (quantity in mg/unit) 
Hydroxy propyl methyl cellulose 6.06 NA NA NA 6.46 6.46 NA NA NA NA 
Hydroxy propyl cellulose NA 6.06 5.45 4.45 NA NA 4.97 4.7 4.78 4.36 
Talc 22.4 22.4 20.1 16.5 23.66 23.66 18.4 17.72 17.72 16.15 
Dibutyl sebacate 0.7 NA NA NA NA NA NA NA NA NA 
Magnesium stearate 1.1 1.7 1.56 1.27 1.85 1.85 1.42 1.37 1.72 1.51 
Enteric coating (quantity in mg/unit) 
Eudragit 24.7 22.1 28.4 29.2 36.9 36.9 30.5 19.3 27.6 26.8 
Tri ethyl citrate 2.48 2.22 2.84 2.95 3.7 3.7 3.06 NA 2.74 2.69 
Acetyl tri butyl citrate NA NA NA NA NA NA NA 1.92 NA NA 
Glyceryl mono stearate II 2.21 1.98 2.53 2.69 3.3 3.3 3.06 1.73 2.48 2.4 
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Table 04: Process parameters  
Sl. No, Parameter Drug layering Barrier coating Enteric coating 
1 Inlet Temperature (°C)  30-42 32-41 32-35 
2 Product Temperature (°C)  28-30 28-32 22-25 
3 Air inlet (CFM) 40-45 40-48 40-45 
4 Spray rate (RPM) 8-10 6-8 10-12 
5 Spray atomization (Bars) 1.6-1.4 1.4-1.6 1.6-1.8 
 
Evaluation Parameters: 
The following methods were done for the Evaluation of 
multi unit particulates like particle size distribution, bulk 
density, angle of repose, compressibility index, moisture 
content, assay, acid resistance, dissolution. 
Flow properties of the Pellets 
The flow properties of pellets were done by angle of 
repose, bulk density, tapped density, compressibility 
index and hausner’s ratio. The below table showed 
results of pellets and their properties  
 
Table 05: Flow properties of pellets  
Evaluation 
parameter 
Angle of 
repose 
Bulk 
density g/cc 
Tapped density 
g/cc 
Compressibility 
index 
Hausner’s 
ratio 
F1 23.9±0.22 0.76±0.022 0.65±0.12 13.84±0.04 0.88±0.016 
F2 23.7±0.19 0.74±0.042 0.66±0.13 12.67±0.011 0.87±0.018 
F3 22.5±0.10 0.75±0.021 0.66±0.24 13.36±0.041 0.86±0.092 
F4 23.1±0.28 0.71±0.022 0.64±0.35 13.13±0.052 0.8±0.020 
F5 22.6±0.18 0.72±0.023 0.65±0.16 12.31±0.067 0.87±0.031 
F6 21.4±0.13 0.77±0.014 0.66±0.37 13.43±0.038 0.86±0.012 
F7 23.1±0.17 0.76±0.035 0.65±0.21 13.83±0.018 0.87±0.053 
F8 22.8±0.25 0.73±0.016 0.64±0.23 12.93±0.029 0.86±0.014 
F9 23.5±0.21 0.74±0.021 0.65±0.10 12.63±0.082 0.86±0.0055 
F10 22.2±0.16 0.75±0.029 0.66±0.31 12.61±0.041 0.86±0.076 
 
Capsule filling and Evaluation 
The pellets filled into capsule done by capsule filling 
machine.  Initially, the weights were adjusted by 
dossier knob and locked length adjusted by locking 
pin. The capsules was tested in disintegration 
apparatus in 0.1N HCl 1000 ml at 37±0.5°C   
Table 06: Capsule filling and evaluation  
Batch no 
Fill weight 
(mg) 
Weight variation 
(%) 
Locked 
length(mm) DT (min) 
F1 104.8 ± 1.4 0.61±0.008 14.4±0.5 8.71±0.27 
F2 97.68±1.3 1.21±0.006 14.3±0.5 8.54±0.34 
F3 104.68±1.5 1.35±0.007 14.4±0.5 8.61±0.31 
F4 102.4±1.2 1.61±0.002 14.3±0.4 8.31±0.34 
F5 106.2±2.1 0.83±0.007 14.2±0.3 8.67±0.41 
F6 101.5±1.7 0.41±0.008 14.3±0.2 8.16±0.52 
F7 102.7±1.6 1.23±0.004 14.1±0.7 8.24±0.36 
F8 98.7±1.6 0.86±0.006 14.3±0.5 8.61±0.43 
F9 105.5±1.8 0.93±0.0021 14.2±0.6 8.23±0.57 
F10 106.7±1.3 1.2±0.002 14.1±0.3 8.65±0.52 
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RESULTS AND DISCUSSION: 
Assay and Moisture content 
Assay percentage of the Innovator product was 
99.8±1.92, Assay percentage of F1 and F2 
formulation was 98.2±1.56, 97.6±1.75 and the 
optimized formulation F10 showed assay percentage 
of 98.7±1.79 which is in limit and matches the 
marketed product. Moisture content of innovator 
product, F1and F2 formulation was 5.8±2.41, 
5.8±2.41, 5.1±1.7 respectively and the moisture 
content of optimized formulation F10, 5.9±2.16 was 
comparable with the innovator product. 
Table 07: Assay and Moisture content of pellets 
TEST Assay ( 98-102% USP) Moisture Content NMT 8% (USP) 
RLD (%) 99.8±1.92 5.8±2.41 
F1 98.2±1.56 5.1±1.7 
F2 97.6±1.75 6.2±1.2 
F3 96.5±2.51 7.1±0.97 
F4 98.3±1.62 6.7±0.94 
F5 97.2±1.89 6.8±1.31 
F6 99.1±1.73 7.2±0.67 
F7 96.1±2.11 7.6±1.69 
F8 96.9±2.31 6.5±1.24 
F9 97.2±2.33 6.6±1.32 
F10 98.7±1.79 5.9±2.16 
 
Acid resistance of initial batches 
The acid resistance is vital to provide protection to 
the pellets during gastric emptying time. The pellets 
were protected by enteric coating for avoiding the 
degradation of drug in acid media. The improvement  
 
 
of acid resistance was done by optimized percentage 
of enteric coating. Average acid resistance values of 
innovator product, F1, F2 is 99.07, 83.53, 85.57 and 
the acid resistance value of optimized formulation 
was 99.25 which are comparable to the innovator 
product or RLD (Reference Listed Drug). 
Table 08: Acid Resistance of pellets  
Formulation Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 Average 
RLD 98.51 99.12 98.61 99.21 99.73 99.01 99.07 
F1 82.91 83.17 82.91 84.31 83.15 84.58 83.53 
F2 85.91 84.62 84.26 86.27 86.93 85.14 85.57 
F3 87.06 86.61 87.68 82.98 83.47 85.25 85.57 
F4 88.31 88.25 87.05 89.27 89.36 89.41 88.60 
F5 94.01 94.21 92.82 92.79 91.04 92.83 92.85 
F6 92.17 95.23 96.51 96.57 96.92 95.28 95.38 
F7 97.21 97.61 97.48 96.03 96.37 96.81 96.90 
F8 98.65 98.75 99.21 99.7 97.21 97.21 98.40 
F9 98.53 98.65 99.17 99.61 99.16 99.53 99.10 
F10 99.62 99.67 99.28 98.89 98.91 99.51 99.25 
 
 
 
 
 
Dissolution 
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The in-vitro percentage drug release of multi units 
contained each formulation done by dissolution method 
and maintained sink condition. The percent drug release of 
formulations F1, F2, F3, F4, F5, F6, F7, F8 F9 is 
67.1±2.19, 72.5±0.98, 76.3±1.91, 88.1±2.51,  71.26±1.91, 
72.9±1.09, 84.9±1.04, 89.2±1.27 94.2±2.03and the 
optimized formulation F10 has a maximum percentage (%) 
drug release of 100.1±1.91. The Q points of the 
formulations are not less than 75%. The optimized 
formulation was compared with innovator product 
(reference listed drug) and almost the similar drug release 
profile was observed. 
 
Table 09: Percentage (%) drug release of formulations 
Trials 
Time(min) 
0 5 15 30 45 
F1 0 6.1±2.31 35.3±2.87 59.2±4.32 67.1±2.19 
F2 0 25.4±1.91 68.2±3.47 71.4±1.95 72.5±0.98 
F3 0 27.7±1.21 64.2±2.36 68.9±2.17 76.3±1.91 
F4 0 30.2±2.17 82.1±1.74 84.7±1.91 88.1±2.51 
F5 0 28.7±4.32 68.42±2.34 73.81±5.8 71.26±1.91 
F6 0 17.2±2.01 58.8±1.08 84.6±1.21 72.9±1.09 
F7 0 18.2±1.2 52.8±1.10 78.4±1.05 84.9±1.04 
F8 0 11.8±0.94 47.4±1.61 72.9±1.35 89.2±1.27 
F9 0 8.3±1.42 42.8±1.03 74.7±1.81 94.2±2.03 
F10 0 3.2±0.92 32.1±2.61 84.7±4.81 100.1±1.91 
 
 
Fig.1: In-Vitro dissolution profile of all formulations 
Table 10: Comparison of Innovator and Optimized formulation (% drug release) 
TIME (MIN) RLD F10 
0 0 0 
5 2.9±1.19 3.2 
15 26.9±3.21 32.1 
30 84.7±5.71 84.7 
45 101.2±2.31 100.1 
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Fig. 2: In-Vitro dissolution profile of innovator and optimized formulation 
Results of stability loaded batch (F10) 
Assay & Moisture content 
Table 11: Assay of stability batch 
Trial Condition Duration  
Assay average 
(%) 
Moisture content 
Average (%) 
F10 (40°C/75%RH) 
1M 99.21±2.23 6.8±1.91 
2M 98.65±1.71 6.1±1.87 
3M 98.71±1.82 6.4±2.01 
6M 98.32±1.86 5.9±2.15 
Acid resistance  
Table 12: Acid Resistance of stability batch 
Unit 
RLD F10 
25°C/60%RH 40°C/75%RH 
Initial 1M 2M 3M 6M 
Unit -1 98.51 98.23 98.50 97.02 99.07 
Unit -2 99.12 97.89 97.27 97.28 99.18 
Unit -3 98.61 97.65 97.63 97.06 99.16 
Unit -4 99.21 97.72 97.01 98.09 99.26 
Unit -5 99.71 98.54 97.08 98.17 99.01 
Unit -6 98.93 98.70 98.09 98.19 99.03 
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In-vitro Dissolution studies  
Table 13: Percentage (%) drug release of stability batch 
Batch 
& 
Month 
Stage 
Time points (min) 
0 5 15 30 45 
% Drug Release 
RLD initial 0 2.9±1.19 26.9±3.21 84.7±5.71 101.2±2.31 
F10 
40°C/75%RH 
1M 
0 8.2±3.21 28.3±4.61 82.14±6.21 98.7±2.97 
40°C/75%RH 
2M 
0 9.1±3.71 27.8±2.13 79.51±3.41 99.52±1.02 
40°C/75%RH 
3M 
0 7.4±4.21 29.63±3.21 81.24±4.57 99.57±1.27 
40°C/75%RH 
6M 
0 4.12±1.93 32.4±3.67 81.7±5.72 99.29±1.06 
 
 
Fig.3: In-Vitro dissolution profile of innovator and stability loaded batch (F10) 
CONCLUSION:  
The drug Esomeprazole magnesium trihydrate was 
found to be suitable for the method of formulating 
into the multiunit particulates using the pellets as 
reservoir units. The release of the drug was 
comparable to the RLD. For the optimization of the 
formula various excipients and their effects on the 
formulation was evaluated and the optimized formula 
was obtained by the multiple (Drug, Barrier, Enteric) 
layering technique containing sugar spheres as the 
core were found to be suitable for formulation. All 
the formulations contained the DR coating in the 
proportion with a slight variation in their percentage 
w/w build up. The evaluation tests which include 
weight variation test fill weight, locked length, assay, 
dissolution, % moisture content, particle size 
distribution, disintegration time. All the formulations 
were evaluated and the formulation F10 was found to 
be the optimized formulation and the batch was 
loaded for the stability at accelerated stability 
condition (40 ± 2oC / 75 ±5% RH). The initial drug 
release was 101.1 ± 1.22 % and it was found to be 
99.29 ± 1.06 % at the end of the 6th month.  
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